Drug Trial Radar · NCT07377838
Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
286
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Sep 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- EHL Bio Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis
Conditions
- Atopic Dermatitis
Interventions
ADSTEM Inj.Biological
hAD-MSC 1.0x10\^8 cells
PlaceboDrug
0.9% Normal Saline Inj.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who achieve a score of 0 or 1 on the validated Investigator's Global Assessment (vIGA) scale at Visit 6, and demonstrate at least a 2-point reduction from baseline(Visit 2)Time frame: From baseline to Weeks 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Soonchunhyang University Cheonan Hospital
Cheonan, Chungcheongnam-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.